A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
Abstract Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor. There is interest in evaluating alternate dosing schedules and novel combinations of pano for the treatment of upper aerodigestive and lung malignancies; thus we evaluated it in combination with Taxol, a chemotherapeutic...
Guardado en:
Autores principales: | Leleesha Samaraweera, Alfred Adomako, Alicia Rodriguez-Gabin, Hayley M. McDaid |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8bf6e32804f94f5480e8b18e2a01b3ef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Senolytics: A Novel Strategy for Neuroprotection in ALS?
por: Alexandra Maximova, et al.
Publicado: (2021) -
Evaluating the neuroprotective impact of senolytic drugs on human vision
por: Nevin W. El-Nimri, et al.
Publicado: (2020) -
Identification of HSP90 inhibitors as a novel class of senolytics
por: Heike Fuhrmann-Stroissnigg, et al.
Publicado: (2017) -
Development of a novel senolytic by precise disruption of FOXO4-p53 complex
por: Utkarsh Tripathi, et al.
Publicado: (2021) -
Senolytic Therapy for Cerebral Ischemia-Reperfusion Injury
por: Songhyun Lim, et al.
Publicado: (2021)